Insmed (NASDAQ:INSM) Chair and Chief Executive William Lewis executed an insider sale and exercised stock options in transactions reported to the Securities and Exchange Commission.
On March 19, 2026, Lewis sold 10,700 shares of Insmed common stock for approximately $1.5 million. The sale was executed at weighted average prices that ranged from $142.17 to $144.11, according to a Form 4 filing.
The filing also shows Lewis exercised options to acquire 10,699 shares of Insmed common stock. The option exercises were at strike prices of $30.46 and $17.16, with the cash cost for those exercises reported as totaling $266839.
Following these reported transactions, Lewis is recorded as directly holding 301185 shares of Insmed common stock. He also has indirect holdings of 233924 shares through the Katie Procter Dynasty Trust, as disclosed in the filing.
The insider activity comes against a backdrop of strong share-price performance over the past year. Insmed shares have appreciated roughly 83% year-over-year, and the stock is trading around $136, a level noted as well above an InvestingPro Fair Value estimate of $106.42. InvestingPro commentary cited in the filing indicates that analysts do not expect Insmed to post a profit in the current year, despite the company showing a 67% increase in revenue.
Investors seeking expanded analysis have access to InvestingPro research offerings, including a Pro Research Report and additional ProTips referenced in the filing, though the filing itself does not provide further proprietary detail.
Insmed's most recent quarterly results for the fourth quarter of 2025 presented a mixed performance. The company reported adjusted earnings per share of -$1.54, missing the consensus expectation of -$1.17, a 31.62% negative surprise. At the same time, Insmed reported fourth-quarter revenue of $263.8 million, exceeding the forecast of $208.2 million and representing a 26.71% positive surprise.
Looking ahead, Insmed issued 2026 revenue guidance for its product Brinsupri that projects more than $1 billion in revenue. H.C. Wainwright highlighted the early revenue guidance as positive for market access and launch metrics, and the firm reiterated a Buy rating with a $230 price target. Stifel also reaffirmed a Buy rating, adjusting its price target to $205 from $212 and citing higher costs as a factor in its revision.
These developments reflect a combination of executive-level portfolio adjustments, strong top-line growth, continued unprofitability on a GAAP basis for the near term as flagged by analysts, and forward-looking revenue expectations tied to Brinsupri. The Form 4 disclosure captures the immediate ownership changes but does not provide commentary from management on the rationale for the option exercises or the share sale.